These Analysts Boost Price Targets On Seagen Following Acquisition News

Pfizer Inc PFE agreed to acquire Seagen Inc SGEN for $229 in cash per Seagen share for a total enterprise value of $43 billion.

Seagen shares jumped 14.5% to close at $197.65 on Monday.

These analysts made changes to their price targets on Seagen following the release of results.

  • Barclays raised the price target on Seagen from $145 to $228. Barclays analyst Gena Wang maintained an Equal-Weight rating.
  • BMO Capital increased the price target on Seagen from $179 to $229. BMO Capital analyst Etzer Darout downgraded the stock from Outperform to Market Perform.

Other analysts also downgraded the stock following the deal announcement.

  • JMP Securities analyst Reni Benjamin downgraded Seagen from Market Outperform to Market Perform.
  • Raymond James analyst Dane Leone downgraded the stock from Strong Buy to Market Perform.
  • Needham analyst Ami Fadia also downgraded Seagen from Buy to Hold.

Check This Out: Lennar, Caleres And 3 Stocks To Watch Heading Into Tuesday

Price Target
Posted In: M&ANewsPrice TargetPre-Market OutlookMarketsAnalyst RatingsTrading IdeasExpert IdeasPT Changes